Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DFN-15 Dose 1 · 1 trial · 1 indication
DFN-15 maximum Plasma Concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| DFN-15 Dose 1 | EXPERIMENTAL | - |
| DFN-15 Dose 2 | EXPERIMENTAL | - |
| DFN-15 Dose 3 | EXPERIMENTAL | - |
| Active Comparator | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DFN-15 Dose 1 | DRUG | - |
| DFN-15 Dose 2 | DRUG | - |
| DFN-15 Dose 3 | DRUG | - |
| Active Comparator | DRUG | - |
Inclusion Criteria: Subjects were male or female, at least 18 years of age but not older than 45 years of age. The main inclusion criteria were: 1. non- or ex-smokers 2. body mass index (BMI) ≥18.50 kg/m2 and \<30.00 kg/m2 3. no clinically significant abnormality found in the 12-lead ECG performed...
DFN-15 Dose 1 is an investigational small molecule being developed by Dr. Reddy's Laboratories Ltd (RDY). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied to assess its bioavailability and dose proportionality.
DFN-15 Dose 1 is being studied for use in healthy volunteers. The Phase 1 trial is designed to evaluate the bioavailability of DFN-15 at different doses and to determine dose proportionality in fasting healthy adults. It is not yet approved for any medical condition.
DFN-15 Dose 1 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting clinical trials to evaluate the drug's pharmacokinetic properties in healthy subjects.
DFN-15 Dose 1 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is being studied in a completed Phase 1 trial that enrolled 16 healthy adult participants in the United States.
DFN-15 Dose 1 has one completed clinical trial, registered under NCT03051685. The study, titled 'Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults,' was a Phase 1 trial conducted in the United States with 16 healthy participants.
DFN-15 Dose 1 is a specific dose level of the investigational drug DFN-15. The clinical trial NCT03051685 evaluates DFN-15 at three different doses, including Dose 1, to compare bioavailability against a comparator and assess dose proportionality in healthy adults.